ERBB2 and breast carcinoma: Similarly, in a single-arm phase 2 study on 493 patients with early stage HER2 positive breast cancer treated with a four-cycle regimen of docetaxel and cyclophosphamide combined with trastuzumab, 95 patients with node negative, ≤ 1 cm tumors had 100% of 3-year disease-free and overall survival rate.